Crown Bioscience Inc.
CrownBio Launches Innovative Inflammatory Disease Models to Advance Pre-Clinical Research
SANTA CLARA, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, announces the launch of pre-clinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) to help inform decision making in pre-clinical drug development. These models mark the first of many the company plans to release as part of our commitment to serve autoimmune and inflammatory disease researchers.
CrownBio has developed mechanistically diverse models of RA and IBD to drive pre-clinical drug development. The models have been scientifically designed to evoke the similar clinical features observed in humans suffering from these conditions, making them ideal systems for pre-clinical researchers developing IBD and RA therapeutics.
The IBD models include, acute dextran sodium sulfate (DSS) challenge and T cell transfer models of IBD, develop symptoms indicative of IBD, including weight loss, colon shortening and an associated inflammation in the gut. While RA models include collagen-induced arthritis and collagen antibody-induced arthritis models that develop the clinical features of arthritis including swollen and inflamed joints.
"Millions of patients endure the pain and discomfort caused by RA and IBD," said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. "Our team led by Joel Tocker, Head of Inflammation, has over 40 years of drug discovery experience in autoimmune and inflammatory diseases to help build ideal models that lead to therapeutic advancements."
"CrownBio is excited to expand the unique advantages of our scientific technology platform into autoimmune and inflammatory disease research," said Jean Pierre Wery, Chief Executive Officer. "We look forward to growing our therapeutic portfolio in this area and delivering valuable insights which drive new discoveries that bring drugs to market, achieving our mission of connecting science to patients."
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.Media Enquiries:
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Shyft Network21.6.2018 20:20 | pressemeddelelse
Shyft Unveils Board of Advisors Comprised of Top Crypto, Industry, and Regulatory Leaders United to Redefine Identity, Regulatory Compliance and Privacy For All
VITEC21.6.2018 19:02 | pressemeddelelse
United Shore Selects VITEC's EZ TV IPTV & Digital Signage Platform for New Headquarters
SEMAFO Inc.21.6.2018 17:25 | pressemeddelelse
SEMAFO Announces Retirement of VP, Exploration & Mine Geology; Announces Geology Team Succession
Bombardier Transportation20.6.2018 11:54 | pressemeddelelse
Bombardier's Chinese Joint Venture Wins Contract to Provide an INNOVIA Automated People Mover System to Shenzhen Airport
Erytech Pharma S.A.20.6.2018 07:32 | pressemeddelelse
ERYTECH to Present at JMP Securities Life Science Conference
Crown Bioscience Inc.19.6.2018 14:01 | pressemeddelelse
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum